Practiceby Lab 10 Get started ›
Crossfire

Do adaptogens like ashwagandha actually balance your stress hormones?

What the experts say

Aviva RommMD · family physician (NPPES taxonomy 207Q00000X, MA licence 253326 and NY licence 9040902; Yale MD awarded 1 Sep 2009, verified in Yale's own thesis repository; stated board certification not confirmed against ABFM) · midwife, apprenticeship-trained, approx. 25 years, current standing not established · herbalist, past president of the American Herbalists Guild and former Medical Director of the American Herbal Pharmacopoeia, both confirmed by the organisations themselves

Take a combination of about three adaptogens daily for at least three months; they normalise adrenal function in either direction, whether you are over-stimulated or depleted.

What it rests onTraditional use in Ayurvedic and Chinese medicine over centuries, where these herbs are the 'Kings' and 'Queens' of the materia medica, plus a stated pharmacological property: 'the chemicals they contain actually help to normalize adrenal function ... they work whether you are experiencing adrenal over-stimulation, or adrenal fatigue.' She also states the category is non-toxic even with long-term use, and gives individual cautions per herb.

Source: avivaromm.com ↗
Jennifer GunterMD · OB/GYN and pain medicine physician

The adaptogen concept does not match the pharmacology, and she would not take ashwagandha.

What it rests onHer argument is specifically against bidirectionality: every trial shows ashwagandha lowers cortisol rather than adapting to need, so it is a unidirectional cortisol suppressant. Since chronic stress raises cortisol early and blunts it later, suppressing cortisol in the late phase could worsen the fatigue and brain fog it is taken for. She adds cholestatic hepatitis inherent to the herb, possible thyroid effects, and that proprietary blends hide the amounts. She grades her own evidence as poor twice in the same passage and concedes the early-phase case as an untested hypothesis.

Source: vajenda.substack.com ↗

Overview

Romm is writing for women under chronic stress, in her own framework of adrenal overdrive progressing to adrenal fatigue, and recommends against use in pregnancy and alongside immunosuppressants. Gunter is writing about a commercially sold cortisol-support blend marketed to perimenopausal women, and her ashwagandha section is framed as personal practice rather than as a population recommendation.

Neither is talking about people with diagnosed adrenal disease, and neither cites a trial with a clinical outcome in the other's population.

Where they agree

More than the framing suggests. Both accept that chronic stress dysregulates the HPA axis. Both accept that the trial evidence for these herbs is small, heterogeneous and often industry-linked; Gunter says so directly and Romm's own claim is graded Insufficient evidence on her own presentation, which offers no trial.

Both hold that a proprietary blend hiding its amounts is worse than a named quantity: Romm publishes exact doses per herb, which is the practice Gunter is asking for. And neither claims a clinical outcome trial exists.

What would settle it

A randomised trial measuring a clinical outcome rather than a cortisol level, stratified by baseline cortisol phase, would settle the bidirectionality question that is the actual dispute. Failing that, a pharmacovigilance series on ashwagandha hepatotoxicity with denominators would settle the safety half, which is currently case reports on one side and silence on the other.

Practice does not pick a winner here

You do, and your call is dated, kept, and yours to change. Follow the people you already trust and what they publish turns into a short daily practice.

Get started

Free to sign up and use. We do not ask for a card.